antiviral and associated therapy - versus potential COVID-19 treatments - for COVID-19 severe or critically pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.97 [0.73, 1.29]< 116%2 studies (2/-)58.5 %some concernnot evaluable moderatecrucial-
deaths 0.86 [0.74, 1.00]< 10%7 studies (7/-)97.6 %some concernnot evaluable moderatecrucial-
deaths (time to event analysis only) 0.85 [0.71, 1.03]< 121%5 studies (5/-)95.3 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.95 [0.55, 1.64]< 10%1 study (1/-)57.3 %NAnot evaluable important-
clinical improvement 0.96 [0.68, 1.35]> 168%4 studies (4/-)40.8 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 0.94 [0.68, 1.30]> 162%5 studies (5/-)35.1 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.10 [0.64, 1.90]> 168%3 studies (3/-)63.9 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 1.01 [0.68, 1.50]> 11%3 studies (3/-)52.1 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.19 [0.98, 1.45]> 10%3 studies (3/-)96.0 %some concernnot evaluable moderateimportant-
hospital discharge 0.82 [0.66, 1.02]> 140%3 studies (3/-)3.5 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.14 [0.03, 0.71]< 10%1 study (1/-)99.1 %NAnot evaluable important-
ICU admission 1.42 [0.68, 2.99]< 10%1 study (1/-)17.7 %NAnot evaluable non important-
off oxygenation 0.98 [0.64, 1.51]> 10%1 study (1/-)46.4 %NAnot evaluable non important-

safety endpoints 00

AE leading to drug discontinuation 2.43 [0.79, 7.45]< 10%1 study (1/-)6.0 %NAnot evaluable important-
related SAE (TRSAE) 1.24 [0.50, 3.11]< 10%1 study (1/-)32.0 %NAnot evaluable important-
serious adverse events 0.90 [0.59, 1.38]< 147%5 studies (5/-)68.1 %some concernnot evaluable moderateimportant-
deep vein thrombosis 0.50 [0.03, 8.10]< 10%1 study (1/-)68.5 %NAnot evaluable non important-
elevated liver enzymes 0.36 [0.13, 1.01]< 10%1 study (1/-)97.3 %NAnot evaluable non important-
hyperbilirubinemia 1.09 [0.42, 2.79]< 10%1 study (1/-)43.1 %NAnot evaluable non important-
long QT 0.90 [0.56, 1.43]< 10%1 study (1/-)67.1 %NAnot evaluable non important-
pulmonary embolism 0.50 [0.03, 8.10]< 10%1 study (1/-)68.5 %NAnot evaluable non important-
renal impairment 1.44 [0.98, 2.10]< 10%2 studies (2/-)3.0 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.